ReviewFrontiers in oncology2026
Mechanisms of immune resistance in microsatellite-stable colorectal cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microsatellite-stable (MSS) colorectal cancer (CRC) accounts for approximately 85% of all CRC cases and exhibits limited responsiveness to immune checkpoint inhibitors (ICIs), representing a major challenge in current cancer immunotherapy. At the tumor-cell intrinsic level, low tumor mutational burden (TMB), impaired neoantigen generation, aberrant activation of oncogenic pathways such as WNT/β-catenin signaling, and defects in interferon-γ signaling contribute to impaired immune recognition and immune escape. Within the TME, the accumulation of immunosuppressive populations, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), together with extracellular matrix remodeling and chemokine dysregulation, establishes an immune-excluded microenvironment that restricts effective antitumor immune responses. Furthermore, metabolic alterations, including enhanced glycolysis, lactate accumulation, and amino acid metabolic reprogramming, impair immune cell function and promote immunosuppression. Epigenetic modifications, including DNA methylation, histone remodeling, and non-coding RNA regulation, further contribute to the silencing of immune-related genes and reinforcement of immune evasion. In addition, recent advances in single-cell sequencing and spatial transcriptomics have provided unprecedented insights into the cellular heterogeneity and spatial organization of MSS CRC immune ecosystems. This review summarizes current knowledge regarding the molecular and cellular mechanisms driving immune resistance in MSS CRC and discusses future therapeutic opportunities for transforming immunologically "cold" MSS tumors into responsive immune microenvironments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.